Vaccines Market Size, Share & Industry Analysis, By Type (Live Attenuated, Inactivated, Recombinant, mRNA Vaccine, Viral Vectors Vaccines, Toxoid), By Route of Administration (Parenteral & Oral), By Disease Indication (Viral Diseases {Hepatitis A, Hepatitis B, Polio, RSV, Influenza, HPV, Measles/Mumps/Rubella, Rotavirus, Shingles (Herpes Zoster)} & Bacterial Diseases {Pneumococcal Disease, Diphtheria, Meningococcal Disease}), By Age Group (Pediatric & Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers), & Regional Forecast, 2026-2034

Last Updated: December 15, 2025 | Format: PDF | Report ID: FBI101769

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Pipeline Analysis, By Key Players
2. Technological Advancements in the Vaccines Market
3. Incidence/Prevalence of Disease Indications, 2025/2026
4. New Product Launches, By Key Players
5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
6. Analysis: Biologics Trends in the Global Market
7. Impact of Tariff on the Vaccines Market
Global Vaccines Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. Live Attenuated
  4. Viral Vector
  5. mRNA
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis A
    2. Hepatitis B
    3. Influenza
    4. Human Papillomavirus
    5. Measles/Mumps/Rubella
    6. Rotavirus
    7. Herpes Zoster
    8. Polio
    9. RSV
    10. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
  3. Market Analysis, Insights and Forecast – By Age Group
    1. Pediatric
    2. Adolts
  4. Market Analysis, Insights and Forecast – By Distribution Channel
    1. Hospital & Retail Pharmacies
    2. Government Suppliers
    3. Others
  5. Market Analysis, Insights and Forecast – By Region
    1. North America
    2. Europe
    3. Asia Pacific
    4. Latin America
    5. Middle East & Africa
North America Vaccines Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. Live Attenuated
  4. Viral Vector
  5. mRNA
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis A
    2. Hepatitis B
    3. Influenza
    4. Human Papillomavirus
    5. Measles/Mumps/Rubella
    6. Rotavirus
    7. Herpes Zoster
    8. Polio
    9. RSV
    10. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
  3. Market Analysis, Insights and Forecast – By Age Group
    1. Pediatric
    2. Adolts
  4. Market Analysis, Insights and Forecast – By Distribution Channel
    1. Hospital & Retail Pharmacies
    2. Government Suppliers
    3. Others
  5. Market Analysis, Insights and Forecast – By Country
    1. U.S.
      1. By Type
    2. Canada
      1. By Type
Europe Vaccines Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. Live Attenuated
  4. Viral Vector
  5. mRNA
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis A
    2. Hepatitis B
    3. Influenza
    4. Human Papillomavirus
    5. Measles/Mumps/Rubella
    6. Rotavirus
    7. Herpes Zoster
    8. Polio
    9. RSV
    10. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
  3. Market Analysis, Insights and Forecast – By Age Group
    1. Pediatric
    2. Adolts
  4. Market Analysis, Insights and Forecast – By Distribution Channel
    1. Hospital & Retail Pharmacies
    2. Government Suppliers
    3. Others
  5. Market Analysis, Insights and Forecast – By Country/Sub-region
    1. U.K.
      1. By Type
    2. Germany
      1. By Type
    3. France
      1. By Type
    4. Spain
      1. By Type
    5. Italy
      1. By Type
    6. Scandinavia
      1. By Type
    7. Rest of Europe
      1. By Type
Asia Pacific Vaccines Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. Live Attenuated
  4. Viral Vector
  5. mRNA
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis A
    2. Hepatitis B
    3. Influenza
    4. Human Papillomavirus
    5. Measles/Mumps/Rubella
    6. Rotavirus
    7. Herpes Zoster
    8. Polio
    9. RSV
    10. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
  3. Market Analysis, Insights and Forecast – By Age Group
    1. Pediatric
    2. Adolts
  4. Market Analysis, Insights and Forecast – By Distribution Channel
    1. Hospital & Retail Pharmacies
    2. Government Suppliers
    3. Others
  5. Market Analysis, Insights and Forecast – By Country/Sub-region
    1. Japan
      1. By Type
    2. China
      1. By Type
    3. India
      1. By Type
    4. Australia
      1. By Type
    5. Southeast Asia
      1. By Type
    6. Rest of Asia Pacific
      1. By Type
Latin America Vaccines Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. Live Attenuated
  4. Viral Vector
  5. mRNA
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis A
    2. Hepatitis B
    3. Influenza
    4. Human Papillomavirus
    5. Measles/Mumps/Rubella
    6. Rotavirus
    7. Herpes Zoster
    8. Polio
    9. RSV
    10. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
  3. Market Analysis, Insights and Forecast – By Age Group
    1. Pediatric
    2. Adolts
  4. Market Analysis, Insights and Forecast – By Distribution Channel
    1. Hospital & Retail Pharmacies
    2. Government Suppliers
    3. Others
  5. Market Analysis, Insights and Forecast – By Country/Sub-region
    1. Brazil
      1. By Type
    2. Mexico
      1. By Type
    3. Rest of Latin America
      1. By Type
Middle East & Africa Vaccines Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. Live Attenuated
  4. Viral Vector
  5. mRNA
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis A
    2. Hepatitis B
    3. Influenza
    4. Human Papillomavirus
    5. Measles/Mumps/Rubella
    6. Rotavirus
    7. Herpes Zoster
    8. Polio
    9. RSV
    10. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
  3. Market Analysis, Insights and Forecast – By Age Group
    1. Pediatric
    2. Adolts
  4. Market Analysis, Insights and Forecast – By Distribution Channel
    1. Hospital & Retail Pharmacies
    2. Government Suppliers
    3. Others
  5. Market Analysis, Insights and Forecast – By Country/Sub-region
    1. GCC Countries
      1. By Type
    2. South Africa
      1. By Type
    3. Rest of Middle East & Africa
      1. By Type
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles
  1. Pfizer Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  2. Sanofi
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  3. CSL
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  4. AstraZeneca
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  5. Bavarian Nordic
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  6. GSK plc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  7. EMERGENT
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  8. Merck & Co., Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  9. Inovio Pharmaceuticals, Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Pipeline Analysis, By Key Players
2. Technological Advancements in the Vaccines Market
3. Incidence/Prevalence of Disease Indications, 2025/2026
4. New Product Launches, By Key Players
5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
6. Analysis: Biologics Trends in the Global Market
7. Impact of Tariff on the Vaccines Market
Global Vaccines Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. Live Attenuated
  4. Viral Vector
  5. mRNA
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis A
    2. Hepatitis B
    3. Influenza
    4. Human Papillomavirus
    5. Measles/Mumps/Rubella
    6. Rotavirus
    7. Herpes Zoster
    8. Polio
    9. RSV
    10. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
  3. Market Analysis, Insights and Forecast – By Age Group
    1. Pediatric
    2. Adolts
  4. Market Analysis, Insights and Forecast – By Distribution Channel
    1. Hospital & Retail Pharmacies
    2. Government Suppliers
    3. Others
  5. Market Analysis, Insights and Forecast – By Region
    1. North America
    2. Europe
    3. Asia Pacific
    4. Latin America
    5. Middle East & Africa
North America Vaccines Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. Live Attenuated
  4. Viral Vector
  5. mRNA
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis A
    2. Hepatitis B
    3. Influenza
    4. Human Papillomavirus
    5. Measles/Mumps/Rubella
    6. Rotavirus
    7. Herpes Zoster
    8. Polio
    9. RSV
    10. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
  3. Market Analysis, Insights and Forecast – By Age Group
    1. Pediatric
    2. Adolts
  4. Market Analysis, Insights and Forecast – By Distribution Channel
    1. Hospital & Retail Pharmacies
    2. Government Suppliers
    3. Others
  5. Market Analysis, Insights and Forecast – By Country
    1. U.S.
      1. By Type
    2. Canada
      1. By Type
Europe Vaccines Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. Live Attenuated
  4. Viral Vector
  5. mRNA
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis A
    2. Hepatitis B
    3. Influenza
    4. Human Papillomavirus
    5. Measles/Mumps/Rubella
    6. Rotavirus
    7. Herpes Zoster
    8. Polio
    9. RSV
    10. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
  3. Market Analysis, Insights and Forecast – By Age Group
    1. Pediatric
    2. Adolts
  4. Market Analysis, Insights and Forecast – By Distribution Channel
    1. Hospital & Retail Pharmacies
    2. Government Suppliers
    3. Others
  5. Market Analysis, Insights and Forecast – By Country/Sub-region
    1. U.K.
      1. By Type
    2. Germany
      1. By Type
    3. France
      1. By Type
    4. Spain
      1. By Type
    5. Italy
      1. By Type
    6. Scandinavia
      1. By Type
    7. Rest of Europe
      1. By Type
Asia Pacific Vaccines Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. Live Attenuated
  4. Viral Vector
  5. mRNA
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis A
    2. Hepatitis B
    3. Influenza
    4. Human Papillomavirus
    5. Measles/Mumps/Rubella
    6. Rotavirus
    7. Herpes Zoster
    8. Polio
    9. RSV
    10. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
  3. Market Analysis, Insights and Forecast – By Age Group
    1. Pediatric
    2. Adolts
  4. Market Analysis, Insights and Forecast – By Distribution Channel
    1. Hospital & Retail Pharmacies
    2. Government Suppliers
    3. Others
  5. Market Analysis, Insights and Forecast – By Country/Sub-region
    1. Japan
      1. By Type
    2. China
      1. By Type
    3. India
      1. By Type
    4. Australia
      1. By Type
    5. Southeast Asia
      1. By Type
    6. Rest of Asia Pacific
      1. By Type
Latin America Vaccines Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. Live Attenuated
  4. Viral Vector
  5. mRNA
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis A
    2. Hepatitis B
    3. Influenza
    4. Human Papillomavirus
    5. Measles/Mumps/Rubella
    6. Rotavirus
    7. Herpes Zoster
    8. Polio
    9. RSV
    10. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
  3. Market Analysis, Insights and Forecast – By Age Group
    1. Pediatric
    2. Adolts
  4. Market Analysis, Insights and Forecast – By Distribution Channel
    1. Hospital & Retail Pharmacies
    2. Government Suppliers
    3. Others
  5. Market Analysis, Insights and Forecast – By Country/Sub-region
    1. Brazil
      1. By Type
    2. Mexico
      1. By Type
    3. Rest of Latin America
      1. By Type
Middle East & Africa Vaccines Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. Live Attenuated
  4. Viral Vector
  5. mRNA
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis A
    2. Hepatitis B
    3. Influenza
    4. Human Papillomavirus
    5. Measles/Mumps/Rubella
    6. Rotavirus
    7. Herpes Zoster
    8. Polio
    9. RSV
    10. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
  3. Market Analysis, Insights and Forecast – By Age Group
    1. Pediatric
    2. Adolts
  4. Market Analysis, Insights and Forecast – By Distribution Channel
    1. Hospital & Retail Pharmacies
    2. Government Suppliers
    3. Others
  5. Market Analysis, Insights and Forecast – By Country/Sub-region
    1. GCC Countries
      1. By Type
    2. South Africa
      1. By Type
    3. Rest of Middle East & Africa
      1. By Type
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles
  1. Pfizer Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  2. Sanofi
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  3. CSL
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  4. AstraZeneca
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  5. Bavarian Nordic
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  6. GSK plc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  7. EMERGENT
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  8. Merck & Co., Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  9. Inovio Pharmaceuticals, Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)

Read Less

List of Figures

Figure 1: Global Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2026 & 2034

Figure 2: Global Vaccines Market Value Share (%), by Type, 2026 & 2034

Figure 3: Global Vaccines Market Value Share (%), by Route of Administration, 2026 & 2034

Figure 4: Global Vaccines Market Value Share (%), by Disease Indication, 2026 & 2034

Figure 5: Global Vaccines Market Value Share (%), by Age Group, 2026 & 2034

Figure 6: Global Vaccines Market Value Share (%), by Distribution Channel, 2026 & 2034

Figure 7: Global Vaccines Market Value (USD billion), by Region, 2026 & 2034

Figure 8: North America Vaccines Market Value (USD billion), by Type, 2026 & 2034

Figure 9: North America Vaccines Market Value Share (%), by Type, 2025

Figure 10: North America Vaccines Market Value (USD billion), by Route of Administration, 2026 & 2034

Figure 11: North America Vaccines Market Value Share (%), by Route of Administration, 2025

Figure 12: North America Vaccines Market Value (USD billion), by Disease Indication, 2026 & 2034

Figure 13: North America Vaccines Market Value Share (%), by Disease Indication, 2025

Figure 14: North America Vaccines Market Value (USD billion), by Age Group, 2026 & 2034

Figure 15: North America Vaccines Market Value Share (%), by Age Group, 2025

Figure 16: North America Vaccines Market Value (USD billion), by Distribution Channel, 2026 & 2034

Figure 17: North America Vaccines Market Value Share (%), by Distribution Channel, 2025

Figure 18: North America Vaccines Market Value (USD billion), By Country, 2026 & 2034

Figure 19: North America Vaccines Market Value Share (%), By Country, 2025

Figure 20: Europe Vaccines Market Value (USD billion), by Type, 2026 & 2034

Figure 21: Europe Vaccines Market Value Share (%), by Type, 2025

Figure 22: Europe Vaccines Market Value (USD billion), by Route of Administration, 2026 & 2034

Figure 23: Europe Vaccines Market Value Share (%), by Route of Administration, 2025

Figure 24: Europe Vaccines Market Value (USD billion), by Disease Indication, 2026 & 2034

Figure 25: Europe Vaccines Market Value Share (%), by Disease Indication, 2025

Figure 26: Europe Vaccines Market Value (USD billion), by Age Group, 2026 & 2034

Figure 27: Europe Vaccines Market Value Share (%), by Age Group, 2025

Figure 28: Europe Vaccines Market Value (USD billion), by Distribution Channel, 2026 & 2034

Figure 29: Europe Vaccines Market Value Share (%), by Distribution Channel, 2025

Figure 30: Europe Vaccines Market Value (USD billion), By Country/ Sub-region, 2026 & 2034

Figure 31: Europe Vaccines Market Value Share (%), By Country/ Sub-region, 2025

Figure 32: Asia Pacific Vaccines Market Value (USD billion), by Type, 2026 & 2034

Figure 33: Asia Pacific Vaccines Market Value Share (%), by Type, 2025

Figure 34: Asia Pacific Vaccines Market Value (USD billion), by Route of Administration, 2026 & 2034

Figure 35: Asia Pacific Vaccines Market Value Share (%), by Route of Administration, 2025

Figure 36: Asia Pacific Vaccines Market Value (USD billion), by Disease Indication, 2026 & 2034

Figure 37: Asia Pacific Vaccines Market Value Share (%), by Disease Indication, 2025

Figure 38: Asia Pacific Vaccines Market Value (USD billion), by Age Group, 2026 & 2034

Figure 39: Asia Pacific Vaccines Market Value Share (%), by Age Group, 2025

Figure 40: Asia Pacific Vaccines Market Value (USD billion), by Distribution Channel, 2026 & 2034

Figure 41: Asia Pacific Vaccines Market Value Share (%), by Distribution Channel, 2025

Figure 42: Asia Pacific Vaccines Market Value (USD billion), By Country/ Sub-region, 2026 & 2034

Figure 43: Asia Pacific Vaccines Market Value Share (%), By Country/ Sub-region, 2025

Figure 44: Latin America Vaccines Market Value (USD billion), by Type, 2026 & 2034

Figure 45: Latin America Vaccines Market Value Share (%), by Type, 2025

Figure 46: Latin America Vaccines Market Value (USD billion), by Route of Administration, 2026 & 2034

Figure 47: Latin America Vaccines Market Value Share (%), by Route of Administration, 2025

Figure 48: Latin America Vaccines Market Value (USD billion), by Disease Indication, 2026 & 2034

Figure 49: Latin America Vaccines Market Value Share (%), by Disease Indication, 2025

Figure 50: Latin America Vaccines Market Value (USD billion), by Age Group, 2026 & 2034

Figure 51: Latin America Vaccines Market Value Share (%), by Age Group, 2025

Figure 52: Latin America Vaccines Market Value (USD billion), by Distribution Channel, 2026 & 2034

Figure 53: Latin America Vaccines Market Value Share (%), by Distribution Channel, 2025

Figure 54: Latin America Vaccines Market Value (USD billion), By Country/ Sub-region, 2026 & 2034

Figure 55: Latin America Vaccines Market Value Share (%), By Country/ Sub-region, 2025

Figure 56: Middle East & Africa Vaccines Market Value (USD billion), by Type, 2026 & 2034

Figure 57: Middle East & Africa Vaccines Market Value Share (%), by Type, 2025

Figure 58: Middle East & Africa Vaccines Market Value (USD billion), by Route of Administration, 2026 & 2034

Figure 59: Middle East & Africa Vaccines Market Value Share (%), by Route of Administration, 2025

Figure 60: Middle East & Africa Vaccines Market Value (USD billion), by Disease Indication, 2026 & 2034

Figure 61: Middle East & Africa Vaccines Market Value Share (%), by Disease Indication, 2025

Figure 62: Middle East & Africa Vaccines Market Value (USD billion), by Age Group, 2026 & 2034

Figure 63: Middle East & Africa Vaccines Market Value Share (%), by Age Group, 2025

Figure 64: Middle East & Africa Vaccines Market Value (USD billion), by Distribution Channel, 2026 & 2034

Figure 65: Middle East & Africa Vaccines Market Value Share (%), by Distribution Channel, 2025

Figure 66: Middle East & Africa Vaccines Market Value (USD billion), By Country/ Sub-region, 2026 & 2034

Figure 67: Middle East & Africa Vaccines Market Value Share (%), By Country/ Sub-region, 2025

Figure 68: Global Vaccines Market Share (%), By Company, 2025

List of Tables

Table 1: Global Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 2: Global Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034

Table 3: Global Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034

Table 4: Global Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034

Table 5: Global Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034

Table 6: Global Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034

Table 7: Global Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 8: Global Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034

Table 10: North America Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034

Table 11: North America Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034

Table 12: North America Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034

Table 13: North America Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034

Table 14: North America Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034

Table 15: North America Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 16: North America Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034

Table 17: U.S. Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 18: Canada Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 19: Europe Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 20: Europe Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034

Table 21: Europe Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034

Table 22: Europe Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034

Table 23: Europe Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034

Table 24: Europe Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034

Table 25: Europe Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 26: Europe Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

Table 27: Germany Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 28: France Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 29: U.K. Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 30: Italy Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 31: Spain Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 32: Scandinavia Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 33: Rest of Europe Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 34: Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 35: Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034

Table 36: Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034

Table 37: Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034

Table 38: Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034

Table 39: Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034

Table 40: Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 41: Asia Pacific Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

Table 42: India Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 43: China Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 44: Japan Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 45: Australia Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 46: South East Asia Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 47: Rest of Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 48: Latin America Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 49: Latin America Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034

Table 50: Latin America Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034

Table 51: Latin America Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034

Table 52: Latin America Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034

Table 53: Latin America Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034

Table 54: Latin America Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 55: Latin America Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

Table 56: Brazil Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 57: Mexico Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 58: Rest of Latin America Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 59: Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 60: Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034

Table 61: Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034

Table 62: Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034

Table 63: Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034

Table 64: Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034

Table 65: Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 66: Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

Table 67: GCC Countries Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 68: South Africa Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

Table 69: Rest of Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034

STUDY PERIOD: 2021-2034
BASE YEAR: 2025
HISTORICAL DATA: 2021-2024
NO OF PAGES: 238

Buy Now

Download Free Sample

Security Code

Growth Advisory Services

Clients

Related Reports

Get In Touch With Us

US +1 833 909 2966 ( Toll Free )

UK +44 808 502 0280 ( Toll Free )

+91 744 740 1245 (APAC)
sales@fortunebusinessinsights.com